Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck : quarterly profit beats estimates; shares gain

07/29/2014 | 10:37am EDT
A view of the Merck & Co. campus in Linden, New Jersey

(Reuters) - Merck & Co Inc reported better-than-expected quarterly results on Tuesday, helped by strong sales of consumer products and medicines for arthritis and HIV, sending its shares up more than 1 percent in morning trading.

Merck, the No. 2 U.S. drugmaker, has been busy with deal-making in recent months, including an agreement to sell its consumer care business to Germany’s Bayer AG for $14.2 billion. In June, it agreed to buy Idenix Pharmaceuticals Inc for $3.85 billion and hopes to combine the two companies' most promising drugs to produce a faster, more effective cure for hepatitis C.

Chief Executive Kenneth Frazier, in a conference call with analysts on Tuesday, said Merck was not interested in major acquisitions, but instead favors smaller "bolt-on" deals like the Idenix transaction.

Merck is counting on its experimental drugs, including an immuno-oncology drug called pembrolizumab, to help drive revenue and earnings growth in coming years, Frazier said.

The company plans to launch pembrolizumab by late October for treatment of melanoma and is testing the drug for cancers of the lung, head and neck and bladder. It plans to introduce insomnia drug Suvorexant, long been delayed by safety concerns, by late 2014 or 2015, if it is approved by regulators.

"Merck will likely have another flattish year in 2014 in terms of financial performance but then growth should return more consistently thereafter," helped by new drugs, Sanford Bernstein analyst Tim Anderson said in a research note.

Merck shares were up 1.3 percent at $58.72.

The company earned $2.03 billion, or 68 cents per share, in the second quarter. That compares with $906 million, or 30 cents per share, in the year-earlier period, when it took charges for acquisitions and restructuring.

Excluding special items, Merck earned 85 cents per share, topping the average 81 cent forecast of analysts surveyed by Thomson Reuters I/B/E/S.

U.S. rival Pfizer Inc on Tuesday also reported better-than-expected quarterly results.

Merck said it expects full-year earnings of $3.43 to $3.53 per share, tightening its earlier forecast of $3.35 to $3.53. The new outlook included expected dilution of up to 9 cents per share from the Bayer and Idenix deals.

Global revenue slipped 1 percent to $10.93 billion, but exceeded expectations of $10.6 billion.

Sales of consumer care brands, such as its Miralax laxative and Afrin cold remedy, jumped 19 percent to $583 million. Sales of prescription drugs slipped 2 percent to $9.1 billion, hurt by a 21 percent drop for its Nasonex nasal allergy treatment due to generic competition.

Sales of HIV treatment Isentress rose 10 percent to $453 million, while Remicade arthritis drug sales increased 15 percent to $607 million.

Combined sales of Merck's biggest drugs, diabetes treatments Januvia and Janumet, rose 2 percent to $1.58 billion. Their growth has slowed this year with competition from newer drugs.

(Editing by Michele Gershberg, Bernadette Baum and Jeffrey Benkoe)

By Ransdell Pierson

© Reuters 2014
All news about MERCK & CO., INC.
07/23MERCK : FDA Approves KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) Combinat..
07/22ADAGENE : Agrees With Merck on Trials of Its Monoclonal Antibodies With Keytruda..
07/22MERCK : Eisai Win US FDA Approval of Keytruda Plus Lenvima Combination for Certa..
07/22MERCK : FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combin..
07/22FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® Combination for Patients..
07/21MERCK : Teams up with Noxxon to Evaluate NOX-A12 in Combination With Keytruda in..
07/21NOXXON Pharma N.V. Enters Second Clinical Collaboration with Merck & Co., Inc..
07/21BAYER : Heart Failure Treatment Wins EU Market Authorization
07/21MERCK : Secures European Approval for Verquvo for Chronic Heart Failure
07/21MERCK : VERQUVO® (vericiguat) Approved in the European Union
More news
Financials (USD)
Sales 2021 46 551 M - -
Net income 2021 12 867 M - -
Net Debt 2021 11 752 M - -
P/E ratio 2021 16,5x
Yield 2021 3,37%
Capitalization 196 B 196 B -
EV / Sales 2021 4,47x
EV / Sales 2022 4,06x
Nbr of Employees 73 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 77,54 $
Average target price 94,10 $
Spread / Average Target 21,4%
EPS Revisions
Managers and Directors
Kenneth C. Frazier Chairman & Chief Executive Officer
Robert M. Davis President
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-5.21%195 475
JOHNSON & JOHNSON9.16%432 430
ROCHE HOLDING AG12.39%325 975
PFIZER, INC.13.23%218 198
NOVARTIS AG1.10%207 246